ロード中...
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: Patient management considerations
BACKGROUND: Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsing-remitting multiple sclerosis (MS), is a disease-modifying therapy with potential immunomodulatory and neuroprotective effects. In clinical trials, DMF was associated with reduced white blood c...
保存先:
| 出版年: | Neurol Clin Pract |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Lippincott Williams & Wilkins
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4909524/ https://ncbi.nlm.nih.gov/pubmed/27347439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0000000000000238 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|